search
Back to results

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

Primary Purpose

Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis

Status
Unknown status
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Fructose
Glucose
Sponsored by
Prof. Michael Trauner, MD
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Non-alcoholic Fatty Liver Disease focused on measuring Non-alcoholic Fatty Liver Disease, Non-alcoholic steatohepatitis, NAFLD, NASH

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion criteria

  1. Healthy men and women from 18 to 85, no disease history, no intake of regular medication, drugs, alcohol (alcohol consumption > 140 grams per week (or > 30g/day) 45) or herbals known to affect liver physiology, male and female (1:1), BMI <= 25.
  2. Patients with prior confirmed (biopsy within 6 months prior to study) intrahepatic fat accumulation/simple fatty liver (NAFL), HbA1c < 6.5, male and female (1:1)
  3. Patients with confirmed NASH (biopsy within 6 months prior to study), HbA1c < 6.5, male and female (1:1).
  4. Signed informed consent, willing and able to perform study procedures.

General exclusion criteria (for all groups)

  1. Pregnancy and lactation (blood/urine pregnancy test will be performed for female volunteers at baseline and week 4)
  2. Imprisoned persons
  3. Declined informed consent
  4. Inflammatory bowel conditions (celiac disease, Crohn's disease, ulcerative colitis)
  5. Prior bariatric surgery
  6. Alcoholic steatohepatitis and/or alcohol consumption > 140 grams per week (or > 30g/day) 45
  7. Other liver diseases (autoimmune, genetic, cholestatic, Wilson disease, Weber-Christian disease, partial lipodystrophy of the face sparing type, abetalipoproteinemia, and jejunal diverticulosis with bacterial overgrowth).
  8. Virus hepatitis (A, B, C)
  9. Known allergic reaction to the drugs used (see material and methods)
  10. Intake of drugs known to accumulate intrahepatic lipids and significantly interfere with metabolism (e.g. steroids/glucocorticoids, tamoxifen, amiodarone, perhexiline maleate, antiretroviral agents, tetracycline, minocycline, certain pesticides) 45
  11. Inability or contraindications to perform study procedures
  12. Fructose malabsorption diagnosed by two consecutive positive fructose hydrogen breath test

MRI contraindications Study participants with claustrophobia Study participants carrying

  • a cardiac pacemaker
  • an insulin pump
  • operation clips
  • nerval stimulators
  • implants or prostheses (e.g. ear implants, hip prostheses, heart valve, penile prosthesis)
  • metal parts or metal fragments [e.g. metallic intrauterine devices (IUDs), marrow nail, metallic splinters or munition rests)
  • metallic shunts or stents

Sites / Locations

  • Medical University of Vienna, General Hospital of Vienna Vienna, Vienna, Austria 1090Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

No Intervention

No Intervention

Arm Label

Fructose

Glucose

NAFLD

NASH

Arm Description

Volunteers will be challenged with oral 150g Fructose per day for 56 days.

Volunteers will be challenged with oral 167g Fructose per day for 56 days.

Patients with confirmed simple fatty liver will be compared at baseline with other arms.

Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.

Outcomes

Primary Outcome Measures

Intrahepatic total fat and ipid composition assessed by Magnetic resonance spectroscopy
At baseline and on the last day of the study (day 56) Magnetic resonance spectroscopy will be carried out in healthy volunteers. (Prior and after double-blinded fructose versus glucose consumption for 8 weeks in each healthy volunteer). In NAFLD and NASH patients Magnetic resonance spectroscopy will only be carried out at baseline, as this arms/groups do not undergo an oral fructose/glucose challenge. Baseline measures between healthy volunteers and NAFLD/NASH groups/arms will be compared to assess differences between healthy individuals and patients. Baseline and day 56 measures in healthy volunteers after fructose/glucose consumption will be compared to assess the influence of the dietary challenge.

Secondary Outcome Measures

Full Information

First Posted
February 6, 2014
Last Updated
September 4, 2020
Sponsor
Prof. Michael Trauner, MD
Collaborators
Wiener Wissenschafts-, Forschungs- und Technologiefonds
search

1. Study Identification

Unique Protocol Identification Number
NCT02075164
Brief Title
Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD
Official Title
Unravelling the Pathogenetic Mechanisms of Fructose in Comparison to Glucose Consumption as Multiple Hit in the Pathogenesis and Progression of Non-alcoholic Fatty Liver Disease (NAFLD) - an Exploratory Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Unknown status
Study Start Date
May 2013 (undefined)
Primary Completion Date
June 2021 (Anticipated)
Study Completion Date
December 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Michael Trauner, MD
Collaborators
Wiener Wissenschafts-, Forschungs- und Technologiefonds

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Non-alcoholic fatty liver disease (NAFLD) comprises a spectrum ranging from simple fatty liver over steatohepatitis (NASH) to liver cirrhosis and cancer (HCC) and is a major and increasing health problem affecting nearly 40% of the general population. Moreover, NAFLD is an important risk factor for progression of diabetes and atherosclerosis. However, the pathomechanisms determining disease progression are poorly understood. The overall aim of this project is to test the central hypothesis that excessive fructose consumption provides a multiple metabolic hit in the pathogenesis and progression of NAFLD/NASH by impairment of hepatic lipid homeostasis and mitochondrial function resulting in hepatic lipotoxicity with inflammasome activation and disturbed interorgan cross-talk among insulin sensitive tissues.
Detailed Description
To achieve these goals we will address the following specific hypotheses that Fructose-induced changes in lipid composition of hepatocellular stores determine lipotoxicity which may be associated with abnormalities in mitochondrial function, energy homeostasis, inflammasome activation and cellular injury in progression to NASH, effects which will be compared to glucose Non-invasive characterization of fructose (compared to glucose)-induced lipotoxic hepatic and extrahepatic metabolic risk profiles (lipid composition and energy metabolism) obtained by magnetic resonance spectroscopy (MRS) will identify patients with NASH Severity of fructose (compared to glucose)-induced lipotoxic lipid and adenosine triphosphate (ATP) derangements (identified by MRS) critically determines the degree of insulin resistance and abnormalities in hepatic glucose and lipid metabolism Compensatory hyperinsulinemia, secondary to skeletal muscle insulin resistance, may be a primary mechanism of hepatic lipotoxicity and progression to NASH Gender differences in the hepatic and systemic metabolic response to fructose are mediated by the impact of female sex hormones and their nuclear receptors on hepatic lipid metabolism, mitochondrial function and inflammasome activation. Age differences in the hepatic and systemic metabolic response to fructose are mediated by the impact of age related alterations on hepatic lipid metabolism and mitochondrial function. These key hypotheses will be addressed by a translational research consortium including hepatologists, radiologists, physicists, endocrinologists and specialist in gender medicine allowing an integrated mechanistic approach to NAFLD. The strength of the current proposal comes directly from bridging basic science and clinical perspectives of different disciplines involved in the management of NAFLD, including cutting edge non-invasive technologies such as high field MRS metabolic profiling ('virtual metabolic liver biopsy') and mechanistic in vitro experiments. This project will provide novel mechanistic insights in the role of fructose as emerging hepatic 'toxin' in the pathogenesis and progression of NASH, as increasing health problem in Western society. Moreover, this study will clarify the impact of sex and gender on fructose-induced alterations in hepatic and systemic metabolism, providing a rational and scientific basis for future dietary interventions and regulatory actions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-alcoholic Fatty Liver Disease, Non-alcoholic Steatohepatitis
Keywords
Non-alcoholic Fatty Liver Disease, Non-alcoholic steatohepatitis, NAFLD, NASH

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
56 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Fructose
Arm Type
Experimental
Arm Description
Volunteers will be challenged with oral 150g Fructose per day for 56 days.
Arm Title
Glucose
Arm Type
Experimental
Arm Description
Volunteers will be challenged with oral 167g Fructose per day for 56 days.
Arm Title
NAFLD
Arm Type
No Intervention
Arm Description
Patients with confirmed simple fatty liver will be compared at baseline with other arms.
Arm Title
NASH
Arm Type
No Intervention
Arm Description
Patients with confirmed non-alcoholic steatohepatitis will be compared at baseline with other arms.
Intervention Type
Dietary Supplement
Intervention Name(s)
Fructose
Intervention Description
High oral Fructose challenge (150g per day for 56 days)
Intervention Type
Dietary Supplement
Intervention Name(s)
Glucose
Intervention Description
Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
Primary Outcome Measure Information:
Title
Intrahepatic total fat and ipid composition assessed by Magnetic resonance spectroscopy
Description
At baseline and on the last day of the study (day 56) Magnetic resonance spectroscopy will be carried out in healthy volunteers. (Prior and after double-blinded fructose versus glucose consumption for 8 weeks in each healthy volunteer). In NAFLD and NASH patients Magnetic resonance spectroscopy will only be carried out at baseline, as this arms/groups do not undergo an oral fructose/glucose challenge. Baseline measures between healthy volunteers and NAFLD/NASH groups/arms will be compared to assess differences between healthy individuals and patients. Baseline and day 56 measures in healthy volunteers after fructose/glucose consumption will be compared to assess the influence of the dietary challenge.
Time Frame
Healthy volunteers: Baseline, day 56 (8 weeks); NAFLD/NASH patients: Baseline

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion criteria Healthy men and women from 18 to 85, no disease history, no intake of regular medication, drugs, alcohol (alcohol consumption > 140 grams per week (or > 30g/day) 45) or herbals known to affect liver physiology, male and female (1:1), BMI <= 25. Patients with prior confirmed (biopsy within 6 months prior to study) intrahepatic fat accumulation/simple fatty liver (NAFL), HbA1c < 6.5, male and female (1:1) Patients with confirmed NASH (biopsy within 6 months prior to study), HbA1c < 6.5, male and female (1:1). Signed informed consent, willing and able to perform study procedures. General exclusion criteria (for all groups) Pregnancy and lactation (blood/urine pregnancy test will be performed for female volunteers at baseline and week 4) Imprisoned persons Declined informed consent Inflammatory bowel conditions (celiac disease, Crohn's disease, ulcerative colitis) Prior bariatric surgery Alcoholic steatohepatitis and/or alcohol consumption > 140 grams per week (or > 30g/day) 45 Other liver diseases (autoimmune, genetic, cholestatic, Wilson disease, Weber-Christian disease, partial lipodystrophy of the face sparing type, abetalipoproteinemia, and jejunal diverticulosis with bacterial overgrowth). Virus hepatitis (A, B, C) Known allergic reaction to the drugs used (see material and methods) Intake of drugs known to accumulate intrahepatic lipids and significantly interfere with metabolism (e.g. steroids/glucocorticoids, tamoxifen, amiodarone, perhexiline maleate, antiretroviral agents, tetracycline, minocycline, certain pesticides) 45 Inability or contraindications to perform study procedures Fructose malabsorption diagnosed by two consecutive positive fructose hydrogen breath test MRI contraindications Study participants with claustrophobia Study participants carrying a cardiac pacemaker an insulin pump operation clips nerval stimulators implants or prostheses (e.g. ear implants, hip prostheses, heart valve, penile prosthesis) metal parts or metal fragments [e.g. metallic intrauterine devices (IUDs), marrow nail, metallic splinters or munition rests) metallic shunts or stents
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Trauner, Prof. MD.
Phone
+43140400
Ext
4741
Email
michael.trauner@meduniwien.ac.at
First Name & Middle Initial & Last Name or Official Title & Degree
Michael Krebs, Prof. MD.
Phone
+43140400
Ext
4311
Email
michael.krebs@meduniwien.ac.at
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michael Trauner, Prof. MD
Organizational Affiliation
Division of Gastroenterology and Hepatology Department of Internal Medicine III Medical University of Vienna
Official's Role
Principal Investigator
Facility Information:
Facility Name
Medical University of Vienna, General Hospital of Vienna Vienna, Vienna, Austria 1090
City
Vienna
ZIP/Postal Code
1090
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Michael Trauner, Prof. MD.
Phone
43140400
Ext
4741
Email
michael.trauner@meduniwien.ac.at
First Name & Middle Initial & Last Name & Degree
Christian Kienbacher, MD, MSc
First Name & Middle Initial & Last Name & Degree
Stefan Traussnigg, MD
First Name & Middle Initial & Last Name & Degree
Christian Rechling, MD

12. IPD Sharing Statement

Citations:
PubMed Identifier
31796953
Citation
Smajis S, Gajdosik M, Pfleger L, Traussnigg S, Kienbacher C, Halilbasic E, Ranzenberger-Haider T, Stangl A, Beiglbock H, Wolf P, Lamp T, Hofer A, Gastaldelli A, Barbieri C, Luger A, Trattnig S, Kautzky-Willer A, Krssak M, Trauner M, Krebs M. Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. Am J Clin Nutr. 2020 Feb 1;111(2):369-377. doi: 10.1093/ajcn/nqz271. Erratum In: Am J Clin Nutr. 2020 Feb 1;111(2):490.
Results Reference
derived

Learn more about this trial

Unravelling Mechanisms of Fructose vs Glucose Consumption in the Pathogenesis and Progression of NAFLD

We'll reach out to this number within 24 hrs